News and Trends 6 Jan 2020 BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2020 €5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2020 Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […] January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Dec 2019 European Biotech’s Top News in 2019 With the year coming to a close, it’s time to review the most important biotech news events that took place in the European biotech industry in 2019. It has been a solid year for the European biotech industry. In 2019, venture capital funding in Europe continued to be high after a very good year in […] December 30, 2019 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […] December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA The German biotech CureVac has signed a deal potentially worth over €1B with Danish antibody developer Genmab to develop messenger RNA drugs that carry the instructions for therapeutic antibodies to be produced inside cancer patients. “We believe that the collaboration with Genmab represents the first antibody deal in the field of mRNA,” stated Daniel Menichella, […] December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 Update: First Ever Ebola Vaccine Gets US and EU Approval Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […] December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost The UK gene therapy biotech Freeline Therapeutics is to receive an investment worth €72M (£61.1M) from the UK VC firm Syncona in a Series C round to fund the clinical development of gene therapies for the blood disorder hemophilia B, Fabry disease, and other rare conditions. Of the €72M commitment, Syncona has already wired €36M […] December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 18 Dec 2019 How BioNTech Navigates the Biotech Fundraising Maze BioNTech is on a mission to individualize cancer therapy by developing a range of different innovative therapies, a task that can be a rollercoaster ride, according to its Chief Business and Commercial Officer Sean Marett. It’s been an interesting year for the German biotech. In July the company raised one of the biggest ever European […] December 18, 2019 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 18 Dec 2019 French Biotech Raises €20M to Treat Cannabis Addiction Without Side Effects Bordeaux-based Aelis Farma will use €20M in fresh funding to develop a new treatment for cannabis addiction and cannabis-induced psychosis, as well as a therapy for cognitive deficits in Down’s syndrome. The funding consists of €11M from a financing round coming mostly from regional investors, in addition to €9M raised through research grants. The […] December 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2019 Cellestia Secures €18M to Develop First-in-Class Cancer Drug Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […] December 18, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 18 Dec 2019 Truffle Capital Raises €250M Fund to Launch Life Science Startups The French VC firm Truffle Capital has closed a fund worth €250M with a mission to nurture companies specializing in medical devices and robotics. The fund, named BioMedTech, will be used to create around 12 companies, with a focus on French startups. The majority of the fund, around 60%, came from French investors and the […] December 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email